Neuralstem (CUR) versus Catalent (CTLT) Head-To-Head Contrast

Neuralstem (NASDAQ: CUR) and Catalent (NYSE:CTLT) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Profitability

This table compares Neuralstem and Catalent’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Neuralstem -154,347.81% -148.94% -84.85%
Catalent 5.01% 23.97% 5.24%

Volatility & Risk

Neuralstem has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500. Comparatively, Catalent has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500.

Earnings and Valuation

This table compares Neuralstem and Catalent’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Neuralstem $20,000.00 1,416.53 -$21.07 million ($1.66) -1.13
Catalent $2.08 billion 2.66 $109.80 million $0.87 47.70

Catalent has higher revenue and earnings than Neuralstem. Neuralstem is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Neuralstem and Catalent, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neuralstem 0 0 0 0 N/A
Catalent 0 3 6 0 2.67

Neuralstem currently has a consensus price target of $3.18, indicating a potential upside of 70.05%. Catalent has a consensus price target of $44.00, indicating a potential upside of 6.02%. Given Neuralstem’s higher possible upside, equities analysts clearly believe Neuralstem is more favorable than Catalent.

Insider and Institutional Ownership

7.1% of Neuralstem shares are held by institutional investors. Comparatively, 99.4% of Catalent shares are held by institutional investors. 15.4% of Neuralstem shares are held by company insiders. Comparatively, 1.7% of Catalent shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Catalent beats Neuralstem on 9 of the 13 factors compared between the two stocks.

About Neuralstem

Neuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company’s technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company’s NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke.

About Catalent

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.

Receive News & Ratings for Neuralstem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit